Jove
Visualize
お問い合わせ

関連する概念動画

Prodrugs01:30

Prodrugs

4.0K
Prodrugs are a class of pharmaceutical compounds that undergo a biotransformation process within the body to be converted into a pharmacologically active drug. Prodrugs are designed to improve the therapeutic properties of the parent drug, such as enhancing bioavailability, increasing stability, or reducing toxicity. The concept of prodrugs revolves around modifying the chemical structure of the original drug to make it more effective or convenient for administration.
Prodrugs help overcome...
4.0K
Drug Biotransformation: Overview01:16

Drug Biotransformation: Overview

3.6K
Pharmaceutical substances known as xenobiotics are predominantly lipophilic and nonionized. This enables them to permeate lipid bilayers, such as cell membranes, and interact with intracellular target receptors. Lipophilic drugs have an advantage in crossing biological barriers and reaching their intended sites of action. However, lipophilic drugs often have a restricted capacity for renal expulsion or elimination from the body. When these drugs enter the kidneys and undergo glomerular...
3.6K
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

10.0K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
10.0K
Carrier-Mediated Transport01:06

Carrier-Mediated Transport

1.2K
Carrier-mediated transport is a pivotal process in drug absorption, particularly for lipid-insoluble drugs, and encompasses facilitated diffusion and active transport. Facilitated diffusion allows drugs to move along their concentration gradient without energy expenditure, while active transport utilizes ATP to drive drug movement against this gradient.
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
1.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Bioavailability Enhancement: Drug Stability Enhancement and GI Retention01:05

Bioavailability Enhancement: Drug Stability Enhancement and GI Retention

196
Body:Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
196
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー
  1. ホーム
  2. 細胞外標的タンパク質劣化剤-薬剤結合剤をハイジャックし,薬剤の投与を強化する
  1. ホーム
  2. 細胞外標的タンパク質劣化剤-薬剤結合剤をハイジャックし,薬剤の投与を強化する

関連する実験動画

Targeted Plasma Membrane Delivery of a Hydrophobic Cargo Encapsulated in a Liquid Crystal Nanoparticle Carrier
10:16

Targeted Plasma Membrane Delivery of a Hydrophobic Cargo Encapsulated in a Liquid Crystal Nanoparticle Carrier

Published on: February 8, 2017

8.0K

細胞外標的タンパク質劣化剤-薬剤結合剤をハイジャックし,薬剤の投与を強化する

Fangzhu Zhao1, Yan Wu1, Kaitlin Schaefer1

  • 1Department of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, California 94158, United States.

Journal of the American Chemical Society
|October 15, 2025

PubMed で要約を見る

まとめ
この要約は機械生成です。

退化剤薬結合剤 (DDC) は,抗体薬結合剤と細胞外標的タンパク質の分解を組み合わせることで,がん治療を強化する. DDCは溶解体伝達と細胞毒性を改善し,次世代治療の選択肢を提供します.

さらに関連する動画

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines
05:33

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines

Published on: November 9, 2020

11.0K
Preparation and Characterization of Lipophilic Doxorubicin Pro-drug Micelles
09:56

Preparation and Characterization of Lipophilic Doxorubicin Pro-drug Micelles

Published on: August 2, 2016

15.5K

関連する実験動画

Targeted Plasma Membrane Delivery of a Hydrophobic Cargo Encapsulated in a Liquid Crystal Nanoparticle Carrier
10:16

Targeted Plasma Membrane Delivery of a Hydrophobic Cargo Encapsulated in a Liquid Crystal Nanoparticle Carrier

Published on: February 8, 2017

8.0K
High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines
05:33

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines

Published on: November 9, 2020

11.0K
Preparation and Characterization of Lipophilic Doxorubicin Pro-drug Micelles
09:56

Preparation and Characterization of Lipophilic Doxorubicin Pro-drug Micelles

Published on: August 2, 2016

15.5K

科学分野:

  • 腫瘍学
  • 分子生物学
  • 薬物開発

背景:

  • 抗体ベースの治療法は 腫瘍細胞を標的とするのに不可欠です
  • 抗体-薬物結合体 (ADC) と細胞外標的タンパク質分解 (eTPD) は,リソソームの密輸に依存しています.
  • ADCは抗原内化効率により限界に直面し,eTPDは細胞毒性がない.

研究 の 目的:

  • ADC と eTPD の限界を克服する新しい分解剤-薬物結合体 (DDC) を開発する.
  • eTPDの内細胞とリサイクル能力を活用して リソソムの配分を向上させる.
  • 細胞毒性の強化と抗体療法の有効性を拡大する.

主な方法:

  • 低密度リポタンパク質受容体 (LDLR) とケモカイン受容体 (CXCR7) を利用したDDCの開発.
  • 細胞外膜タンパク質のリゾソーム伝達効率と分解の評価
  • 従来のADCと比較したDDC細胞毒性の評価 in vitro.

主要な成果:

  • LDLRベースの分解剤は,細胞外膜タンパク質の効率的かつ選択的な分解を証明した.
  • 細胞毒性のあるDDCは,従来のADCと比較して,細胞毒性をインビトロで高めた.
  • DDCの二重モードは,現在の抗体療法における内部化と効能の課題に対応しています.
  • 結論:

    • DDCは次世代の抗体治療戦略として有望です
    • このアプローチは,がん治療におけるリゾソーム伝達と細胞毒性の有効性を高めます.
    • DDCは,抗体ベースの治療法の選択肢を拡大し,より広範な有用性と有効性を提供します.